• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/8/25 4:07:25 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGO alert in real time by email
    8-K
    False000166118100016611812025-05-082025-05-08

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of Earliest Event Reported): May 8, 2025

    ORGANOGENESIS HOLDINGS INC.

    (Exact Name of Registrant as specified in its charter)

    Delaware

    001-37906

    98-1329150

    (State or Other Jurisdiction

    of Incorporation)

    (Commission

    File Number)

    (IRS Employer

    Identification No.)

    85 Dan Road

    Canton, MA

    02021

    (Address of principal executive offices)

    (Zip Code)

    (781) 575-0775

    (Registrant’s telephone number, including area code)

    Not Applicable

    (Registrant’s name or former address, if change since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

    Class A Common Stock, $0.0001 par value

     

    ORGO

     

    Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging Growth Company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. ☐


    Item 2.02 Results of Operations and Financial Condition.

    On May 8, 2025, the Company announced via press release its results for the fiscal first quarter ended March 31, 2025. A copy of the Company’s press release is hereby furnished to the Commission and incorporated herein by reference as Exhibit 99.1.

    The information in the press release attached as Exhibit 99.1 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

    Exhibit

    No.

    Description

    99.1

     

    Press Release dated May 8, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Organogenesis Holdings Inc.

    By:

    /s/ Lori Freedman

    Name:

    Lori Freedman

    Title:

    Chief Administrative and Legal Officer

     

    Date: May 8, 2025

     


    Get the next $ORGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ORGO

    DatePrice TargetRatingAnalyst
    6/28/2024$5.00Buy
    Lake Street
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    8/10/2022Outperform → Perform
    Oppenheimer
    11/10/2021$26.00 → $20.00Outperform
    SVB Leerink
    8/10/2021$24.00 → $25.00Outperform
    Credit Suisse
    More analyst ratings

    $ORGO
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Organogenesis Holdings Inc.

      DEF 14A - Organogenesis Holdings Inc. (0001661181) (Filer)

      5/12/25 4:23:13 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Organogenesis Holdings Inc.

      10-Q - Organogenesis Holdings Inc. (0001661181) (Filer)

      5/8/25 4:11:48 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Organogenesis Holdings Inc. (0001661181) (Filer)

      5/8/25 4:07:25 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care